Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

• Main Authors: Qiaoling Yang (Author), Yan Wang (Author), Xuebin Wang (Author), Ping Wang (Author), Boyu Tan (Author), Yijun Li (Author), Huajun Sun (Author), Wenyan Huang (Author), Hongxia Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundTacrolimus is widely used to treat pediatric nephrotic range proteinuria (NRP). Diltiazem, a CYP3A4/5 inhibitor, is often administered with tacrolimus, affecting its pharmacokinetic profile. The impact of this combination on tacrolimus exposure, particularly in CYP3A5*3 genetic polymorphis...